Dat	e: 27. april 2021		
You	r name: Caroline Sindet-	Pedersen	
	nuscript title: Choice of antic lio-Oncology center	coagulants for patients with o	cancer-associated thrombosis – insights from a Danish
Mar	nuscript number (if known)):	
are re third comr list a	elated to the content of you parties whose interests ma nitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	
	ollowing questions apply to <u>iscript only</u> .	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta antih In ite	ins to the epidemiology of ypertensive medication, ev	hypertension, you should yen if that medication is n port for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	⊠ None	
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None Non	
3	Royalties or licenses	None Non	

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None None
13	Other financial or non- financial interests	None

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	e: 24. april 2023		
You	r name: Erik Lerkevang	Grove	
	nuscript title: Choice of antid lio-Oncology center	coagulants for patients with	cancer-associated thrombosis – insights from a Danish
Mar	nuscript number (if known):	
are rethird commits a The famant The aperta antih	elated to the content of yo parties whose interests manitment to transparency and relationship/activity/interest collowing questions apply to ascript only. Buthor's relationships/activities to the epidemiology of ypertensive medication, even	ur manuscript. "Related" ay be affected by the connot does not necessarily intest, it is preferable that you the author's relationship titles/interests should be a hypertension, you should yen if that medication is not port for the work reporte	ps/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plar		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this item.		
,			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from	□ None	
	any entity (if not indicated	Boehringer Ingelheim	Unrestricted research grant
	in item #1 above).	AstraZeneca, Idorsia and Bayer	Investigator in studies sponsored by these 3 companies
3	Royalties or licenses	■ None	

4	Consulting fees	Consultancy fees for organizing & chairing educational symposia: Bayer, Bristol Myers-Squibb, Boehringer Ingelheim, MSD.	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None Lecture fees received from AstraZeneca, Bayer, Pfizer, and Bristol-Myers Squibb.	
6	Payment for expert testimony	None Non	
7	Support for attending meetings and/or travel	□ None AstraZeneca	ESC Congress
8	Patents planned, issued or pending	None Non	
9	Participation on a Data	□ None	
,	Safety Monitoring Board or Advisory Board	Lundbeck Pharma	DSMB member for studies investigating new treatments for migraine
		AstraZeneca, Bristol- Myers Squibb, Bayer, MSD, Novo Nordisk, Pfizer.	Ad hoc advisory board meetings
10	Leadership or fiduciary	□ None	
	role in other board, society, committee or advocacy group, paid or unpaid		Chair of the Danish Society of Thrombosis & Haemostasis
			Nucleus member of WG on Cardiovascular Pharmacotherapy (European Society of Thrombosis and Haemostasis)
			Past Chair of the WG on Thrombocardiology (Danish Society of Cardiology)
			Past Nucleus member of WG Thrombosis (European Society of Cardiology)
11	Stock or stock options	None Non	
10	December of a military and	57.1	
12	Receipt of equipment, materials, drugs, medical		1
	atoriais, arags, modical		

	writing, gifts or other services	
13	Other financial or non-	
	financial interests	

🖾 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Dat	e : 25. apr	fil 2023		
You	ır name:	Maja Hellfritzsch	1	
	Manuscript title: Choice of anticoagulants for patients with cancer-associated thrombosis – insights from a Danish Cardio-Oncology center			
Ma	nuscript nu	ımber (if known):	
are r third comr	elated to th parties wh mitment to	ne content of yo nose interests ma transparency ar	ur manuscript. "Related" ay be affected by the cont	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	following q uscript only		o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta	ains to the	epidemiology of	hypertension, you should	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
			port for the work reported disclosure is the past 36 r	d in this manuscript without time limit. For all months.
			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Sir	nce the initial plar	ning of the work	
1	manuscrip provision of materials,	t for the present of (e.g., funding, of study medical writing, cessing charges,	□ None	
	No time lii item.	mit for this		
				Click TAB in last row to add extra rows
Tim	e frame: pa	st 36 months		
	1 -	_		
2		contracts from	None Non	
	in item #1	(if not indicated above).		
		-		
3	Royalties of	or licenses	None Non	

4 (Consulting fees	None Non
l s r	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None Bayer Bristol-Myers Squibb Pfeizer
6 F	Payment for expert	
	testimony	
7 5	Support for attending	
	meetings and/or travel	None
	Ü	
0 [Deterate alexand issued as	
	Patents planned, issued or pending	None Non
1	pending	
	Participation on a Data	None Non
	Safety Monitoring Board or Advisory Board	
	UI AUVISUI Y DUAI U	
	Leadership or fiduciary	None Non
	role in other board,	
	society, committee or advocacy group, paid or unpaid	
11 5	Stock or stock options	None Non
12 F	Receipt of equipment,	None
r	materials, drugs, medical	
	writing, gifts or other	
5	services	
13 (Other financial or non-	None
	financial interests	
	financial interests	

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	e : 26. april 2023		
You	r name: Morten Lambert	:S	
	nuscript title: Choice of antional disconnection of antional disconnec	coagulants for patients with	cancer-associated thrombosis – insights from a Danish
Mai	nuscript number (if known):	
are re third comr	elated to the content of yo parties whose interests ma	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	ollowing questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta	ins to the epidemiology of	hypertension, you should	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
	m #1 below, report all sup r items, the time frame for	•	d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,		
	etc.) No time limit for this item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses	Mana	
5	noyalties of ficerises	⊠ None	

4	Consulting fees	⊠ None
5	Payment or honoraria for	□ None
	lectures, presentations,	Bayer
	speakers bureaus,	Pfizer
	manuscript writing or	BMS
	educational events	Organon
		AZ
6	Payment for expert	⊠ None
	testimony	
7	Support for attending	⊠ None
	meetings and/or travel	
8	Patents planned, issued or	⊠ None
	pending	Z None
9	Participation on a Data Safety Monitoring Board	None
	or Advisory Board	AZ Délaca
	or ravisory board	Pfizer
10	Leadership or fiduciary	⊠ None
	role in other board,	
	society, committee or advocacy group, paid or unpaid	
11	Stock or stock options	⊠ None
12	Receipt of equipment,	⊠ None
	materials, drugs, medical	
	writing, gifts or other	
	services	
13	Other financial or non-	⊠ None
	financial interests	HOIC
	imanciai interests	
	illianciai interests	

oxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date	27. april 2021		
You	r name: Nina Nouhraves	h	
	nuscript title: Choice of antic lio-Oncology center	coagulants for patients with o	cancer-associated thrombosis – insights from a Danish
Mar	nuscript number (if known)):	
are re third comr list a	elated to the content of you parties whose interests ma nitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont and does not necessarily inc est, it is preferable that yo	
	uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta antih In ite	ins to the epidemiology of ypertensive medication, ev	hypertension, you should yen if that medication is no port for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all nonths.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None Non	
3	Royalties or licenses	None Non	

4	Consulting fees	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	□ None AstraZeneca Bayer
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None None
13	Other financial or non- financial interests	None

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	e : 25. april 2023		
	r name: Thomas Kümler		
Mar		coagulants for patients with	cancer-associated thrombosis – insights from a Danish
Mar	nuscript number (if known)):	
are re third comr	elated to the content of yo parties whose interests ma	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so.
	ollowing questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta	ins to the epidemiology of	hypertension, you should	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
	m #1 below, report all suppritems, the time frame for	•	d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ None	
3	Royalties or licenses		
		ZA TVOTIC	

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non- financial interests	None

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	e: 11. september 2023		
You	r name: Ali Al-Alak		
	nuscript title: Choice of antic lio-Oncology center	coagulants for patients with o	cancer-associated thrombosis – insights from a Danish
Mar	nuscript number (if known)):	
are re third comr list a	elated to the content of you parties whose interests ma nitment to transparency ar relationship/activity/intere ollowing questions apply to	ur manuscript. "Related" ay be affected by the cont nd does not necessarily inc est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit ent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to u do so. ps/activities/interests as they relate to the current
manı	<u>uscript only</u> .		
perta	ins to the epidemiology of	hypertension, you should	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
	m #1 below, report all suppritems, the time frame for		d in this manuscript without time limit. For all nonths.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan	-	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	None Non	
	No time limit for this item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None Non	
3	Royalties or licenses		

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non- financial interests	None

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal